Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement PICI Network Presenters at #KScelltherapy23 Our Impact 2022 Year in Review Announcement PICI Network Researchers to Present at #ASH22 Announcement PICI Network Researchers to Present at #SITC22 Announcement Dana-Farber and Gladstone Institutes Join PICI Network Announcement, Our Impact Parker Institute Researchers Featured at #CICON22